Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA

The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges.

Mesa RA

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.

Mesa RA

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.

Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Mesa RA, Quintás-Cardama A, Verstovsek S

Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.

Mesa RA

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A